主要 报价 日历 论坛
flag

FX.co ★ Aslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD Patients

back back next
typeContent_19130:::2024-04-22T15:18:00

Aslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD Patients

Aslan Pharmaceuticals Ltd. announced on Monday encouraging interim results from their Phase 2 study. The study involved Eblasakimab, a treatment for moderate-to-severe atopic dermatitis in adult patients who had previously been treated with Dupilumab, TREK-DX. The trial successfully met its main goal.

The biopharmaceutical company revealed that a significant 73.3% of patients treated with Eblasakimab saw a remarkable reduction in the severity of their eczema. They experienced a decrease in their Eczema Area Severity Index (EASI) score of at least 75% from the base level, compared to only 14.3% on a placebo.

As it stands, shares in ASLN are currently priced at $0.47. This is a 6.50% decrease from the previous closing price of $0.51, with a volume of 9,589,549.

分享此文章:
back back next
loader...
all-was_read__icon
你现在看过所有最好的出版物。
我们已经在寻找一些有趣的东西......
all-was_read__star
最近发表:
loader...
最近的出版物